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Sprouting angiogenesis expands the embryonic
vasculature enabling survival and homeostasis. Yet
how the angiogenic capacity to form sprouts is
allocated among endothelial cells (ECs) to guarantee
the reproducible anatomy of stereotypical vascular
beds remains unclear. Here we show that Sema-
PlxnD1 signaling, previously implicated in sprout
guidance, represses angiogenic potential to ensure
the proper abundance and stereotypical distribution
of the trunk’s segmental arteries (SeAs). We find
that Sema-PlxnD1 signaling exerts this effect by
antagonizing the proangiogenic activity of vascular
endothelial growth factor (VEGF). Specifically,
Sema-PlxnD1 signaling ensures the proper endothe-
lial abundance of soluble flt1 (sflt1), an alternatively
spliced form of the VEGF receptor Flt1 encoding
a potent secreted decoy. Hence, Sema-PlxnD1
signaling regulates distinct but related aspects of
angiogenesis: the spatial allocation of angiogenic
capacitywithin aprimaryvessel andsproutguidance.
INTRODUCTION
Blood vessels form a pervasive tubular network that distributes
oxygen, nutrients, hormones, and immunity factors. The first
blood vessels assemble de novo via EC coalescence or vasculo-
genesis. Later, they expand via angiogenesis, the growth of new
blood vessels from preexisting ones. In some locales, this
process is stereotypic and vascular sprouts form with evolution-
arily conserved and organ-specific distribution, abundance and
shapes (Carmeliet, 2005; Isogai et al., 2001; Isogai et al., 2003).
For example, zebrafish SeAs sprout bilaterally from the trunk’s
aorta just anterior to each somite boundary (SB) (Figure 1A).
SeA sprouts contain migratory, proliferative and filopodia-rich
arterial angiogenic ECs molecularly distinct from the sedentary
‘‘phalanx’’ ECs remaining in the aorta (De Bock et al., 2009; Siek-Developmann and Lawson, 2007; Torres-Va´zquez et al., 2004). Normally,
only aortic ECs near SBs acquire angiogenic capacity (Ahn et al.,
2000; Childs et al., 2002). It is thought that nonendothelial para-
crine VEGF signals promote angiogenic capacity, while Notch-
mediated lateral inhibition between ECs antagonizes it (Phng
and Gerhardt, 2009; Siekmann et al., 2008). However, the
mRNA expression of vegf-a and Notch pathway genes is incon-
sistent with the distribution of SeA sprouts. vegf-a is not tran-
scribed along SBs, but rather expressed dorsal to the aorta at
both the flanking somites’ centers and the hypochord, a midline
endodermal cell row. Notch pathway genes are expressed con-
tinuously along the aorta or broadly through the body (Hogan
et al., 2009b; Lawson et al., 2002; Leslie et al., 2007; Phng
et al., 2009; Siekmann and Lawson, 2007) (C.M.G., J.B., and
J.T.-V., unpublished data). Hence, other cascades likely modu-
late VEGF and/or Notch signaling at presprouting stages to
enable the stereotypical allocation of angiogenic capacity within
the aorta. Perturbing these unidentified cascades might change
the SeA sprouts’ reproducible number or distribution, the ratio of
aortic ECs that acquire angiogenic capacity, and/or the respon-
siveness of these cells to angiogenic cues.
Besides VEGF and Notch activity, proper SeA development
requires paracrine Sema-Plxn signaling. Type 3 semas (sema3s)
are repulsive guidance cues secreted by somites. Sema3s direct
SeA sprout pathfinding by modulating cytoskeletal dynamics via
the endothelial Sema3-receptor PlxnD1. Hence, sema3 or
plxnD1 inactivation yields similar SeA sprout pathfinding defects
in zebrafish and mice (Gay et al., 2011). Two observations made
in zebrafishmake Sema-PlxnD1 signaling a candidatemodulator
of angiogenic capacity. First, sema3 and plxnD1 expression
begins hours before SeAs sprout from the aorta at 21 hr post-
fertilization (hpf). Second, loss of Sema-PlxnD1 signaling
induces ectopic SeA sprout launching (Childs et al., 2002;
Torres-Va´zquez et al., 2004).
In wild-type (WT) animals SeA sprouts grow dorsally with
a chevron-like shape, bifurcate anteroposteriorly at the neural
tube’s roof level and interconnect with their ipsilateral neighbors
at 32 hpf forming the paired Dorsal Longitudinal Anastomotic
Vessels (DLAVs) (Isogai et al., 2003). In contrast, in plxnD1 (out
of bounds - obd) mutants and plxnD1 morphants, SeA sprouts
are misshaped and interconnect ectopically with their ipsilateralmental Cell 21, 301–314, August 16, 2011 ª2011 Elsevier Inc. 301
Figure 1. Sema-PlxnD1 Signaling Is Cell Autonomously Required within the Endothelium for Proper SeA Sprout Abundance and Distribution
(A and B) 23 hpf vasculatures, green. SBs, red. Horizontal myoseptum (HM), white dotted line. SeA sprouts, numbered. (A) WT. (B) obd.
(C and D) SeA sprout position (C) and abundance (D) in 23 hpf WT and obd. n = 8 WT, 12 obd. Error bars represent SEM. ***p < 0.001.
(E and F) WISH, 28 hpf trunks. Ectopic SeA sprouts, white arrowheads. Riboprobes: flt4 (blue), cdh5 (red). WT (E). obd (F). n = 10/10 WT, 10/10 obd.
(G and H) 32 hpf chimeric vasculatures with ECs of donor (green) and host (red) origin. Examples of ectopic SeA sprouts, white arrowheads.
(A, B, E–H) Anterior, left; dorsal, up. Scale bars represent 30 mm. See Figure S1.
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Sema-PlxnD1 Signaling Limits Angiogenic Potentialneighbors but form properly placed DLAVs (Childs et al., 2002;
Torres-Va´zquez et al., 2004). Thus, we further examined Sema-
PlxnD1’s signaling role during zebrafish SeA development,
finding that it plays a presprouting role as a repressor of the302 Developmental Cell 21, 301–314, August 16, 2011 ª2011 Elsevieaorta’s angiogenic potential—the probability that ECs acquire
angiogenic capacity. This role stems from its ability to promote
sflt1’s endothelial abundance and thus antagonize pro-
angiogenic VEGF activity (Rahimi, 2006). We propose thatr Inc.
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Sema-PlxnD1 Signaling Limits Angiogenic PotentialSema-PlxnD1 signaling allocates angiogenic capacity among
aortic ECs in a reproducible spatial pattern, guaranteeing the
proper abundance and distribution of SeA sprouts.
RESULTS
Lack of Sema-PlxnD1 Signaling Induces Too Many
and Ectopic SeA Sprouts
To investigate if Sema-PlxnD1 signaling modulates angiogenic
capacity we measured SeA sprout abundance and positioning
in WT and obd at 23 hpf, when individual obd SeA sprouts are
readily identifiable as they are yet to interconnect ectopically.
We found obd has almost twice theWT’s number of SeA sprouts,
with most of them launching ectopically (Figures 1A–1D). Hence,
Sema-PlxnD1 signaling limits the abundance and defines the
position of SeA sprouts.
To molecularly verify the angiogenic character of ECs within
obd SeA sprouts, we used whole-mount RNA in situ hybridiza-
tion (WISH) (Moens, 2008) to visualize expression of the pan-
endothelial marker cdh5 (Larson et al., 2004) and flt4/vegfr-3,
which labels arterial angiogenic ECs within SeA sprouts and
the vein (Covassin et al., 2006; Hogan et al., 2009b; Siekmann
and Lawson, 2007). flt4 is expressed in all SeA sprouts and
vein of WT and obd (Figures 1E and 1F), confirming the angio-
genic character of ECs within obd’s SeA sprouts and the lack
of artery/vein differentiation defects in obd (Torres-Va´zquez
et al., 2004).
Loss of Sema-PlxnD1 Signaling Yields More
Angiogenic Cells
To determine if obd’s SeA sprout overabundance is associated
with too many angiogenic ECs we compared the number of EC
nuclei found within developing SeAs and DLAVs of WT and
obd at 21, 23, and 32 hpf. We found that obd’s SeAs/DLAVs
collectively harbor more angiogenic ECs than WT (see Figures
S1A and S1B available online). We next aimed to compare the
WT and obd ratios of angiogenic to phalanx arterial ECs.
However, SeA sprouts arise while the aorta and vein segregate
from each other (Herbert et al., 2009), making the quantification
of early aortic EC abundance unfeasible. We thus instead
counted EC nuclei in the axial vasculature (aorta and vein taken
together) and found that obd shows increased axial vasculature
EC abundance (Figures S1A and S1B). Hence, loss of
Sema-PlxnD1 signaling yields more angiogenic and axial vascu-
lature ECs.
Sema-PlxnD1 Signaling Is Cell-Autonomously Required
within the Endothelium
To ask if Sema-PlxnD1 signaling acts cell autonomously to limit
the number and define the position of SeA sprouts, we per-
formed cell transplants (Carmany-Rampey and Moens, 2006)
to make heterogenotypic WT:obd (WT-to-obd and obd-to-WT)
chimeras. We analyzed these at 32 hpf to determine SeA
sprout abundance and distribution and examine the SeA contri-
bution of ECs from donors and hosts (Figures 1G and 1H). We
found too many SeA sprouts in WT:obd chimeras. As in obd,
some SeA sprouts launched ectopically and others were
positioned correctly. WT ECs were found only within properly
positioned SeA sprouts, while obd ECs contributed toDevelopmisshapen SeAs sprouts at both ectopic and correct positions
(Figures 1G and 1H and Figure S1C). Control homogenotypic
(WT-to-WT and obd-to-obd) chimeras also showed mosaic
SeAs with both host and donor ECs (Figure S1E). Hence, SeAs
are not necessarily of clonal origin, in agreement with results
from prior transplantation and mosaic transgenic labeling exper-
iments (Childs et al., 2002; Siekmann and Lawson, 2007).
obd ECs found within WT hosts contribute to SeAs/DLAVs
much more often than WT ECs contribute to these angiogenic
vessels in obd hosts (Figures S1C, S1D, and S2C). Since obd
ECs show exacerbated angiogenic capacity in a WT environ-
ment this property is not caused by axial vasculature EC
overabundance. Finally, nonendothelial obd cells, like ventral
somitic muscle fibers (Childs et al., 2002), did not influence the
abundance, distribution or anatomical patterning of SeA sprouts
(Figure S1C), consistent with plxnD1’s endothelial-specific
expression (Torres-Va´zquez et al., 2004) and the identical
vascular phenotypes of mice with global or EC-specific plxnD1
inactivation (Gay et al., 2011). Thus, Sema-PlxnD1 signaling
acts cell autonomously within the endothelium to limit angio-
genic potential and ensure the proper abundance and posi-
tioning of SeA sprouts.
Aortic ECs with Less Sema-PlxnD1 Signaling (obd/+)
Become Angiogenic Tip Cells More Often and Are
Enriched in the Aorta’s Dorsal Side
Each SeA sprout has a spearheading tip cell that becomes ‘‘T’’
shaped during DLAV formation and which is trailed by a few stalk
cells (Siekmann and Lawson, 2007). Tip cells embody an
enhanced angiogenic state promoted by increased proangio-
genic signaling and characterized by exacerbated filopodia
dynamics whose acquisition and/or maintenance involves cell
competition (Jakobsson et al., 2010; Leslie et al., 2007; Roca
and Adams, 2007).
Thus, if Sema-PlxnD1 signaling antagonizes angiogenic
potential then ECs with reduced Sema-PlxnD1 signaling levels
should acquire an enhanced angiogenic state more often. To
test this hypothesis, we used cell transplantation experiments
to compare the properties of ECs from WT and obd/+ heterozy-
gotes. These embryos have the same number of ECs within both
the SeAs/DLAVs and the axial vasculature (Figure S2A) and iden-
tical SeA sprout abundance, positioning and patterning
(Figures 2A and 2B). We determined the frequency at which
donor ECs become tip cells in homogenotypic (WT-to-WT and
obd/+-to-obd/+) and heterogenotypic (WT-to-obd/+ and
obd/+-to-WT) chimeras. To ensure competition between donor
and host ECs had occurred, we scored only mosaic SeAs
harboring both donor and host ECs. All chimeras showed
correctly patterned and positioned SeA sprouts (Figures 2C
and 2D and data not shown) and both kinds of homogenotypic
chimeras showed identical donor tip cell percentages (Figure 2E).
In contrast, the donor tip cell percentage was significantly larger
in obd/+-to-WT chimeras and smaller in WT-to-obd/+ chimeras
(Figure 2E).
Hence, the angiogenic capacity and angiogenic positional fate
of aortic ECs is not prespecified but is acquired and/or main-
tained competitively, agreeing with prior related observations
(Jakobsson et al., 2010; Siekmann and Lawson, 2007). Indeed,
within developing SeA sprouts angiogenic cell nuclei swapmental Cell 21, 301–314, August 16, 2011 ª2011 Elsevier Inc. 303
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Figure 2. ECs with Less Sema-PlxnD1 Signaling Tend to Become Tip Cells and Occupy the Aorta’s Dorsal Side
(A and B) 32 hpf vasculatures. EC nuclei (green), membranes (red). SBs, blue. (A) WT. (B) obd/+.
(C and D) 28 hpf vasculatures with ECs of donor (green) and host (red) origin. Asterisks: Tip cells (white), stalk cells (blue).
(E) Percentage of mosaic SeAs with tip cells of donor origin in homogenotypic (gray bars) and heterogenotypic (black bars) chimeras. n = 27 WT to obd/+, n = 18
obd/+ to obd/+, n = 38 obd/+ to WT, n = 34 WT to WT. Error bars represent SEM.
(F) Percentage of ECs of donor origin found within the dorsal side of the host’s arterial tree in homogenotypic (gray bar) and heterogenotypic (black bar) chimeras.
(E and F) *p < 0.05, **p < 0.01, ***p < 0.001. Error bars represent SEM. n = 24 WT to WT, n = 32 obd/+ to WT.
(A–D) Anterior, left; dorsal, up. Scale bars represent 30 mm. See Figure S2 and Movie S1.
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Sema-PlxnD1 Signaling Limits Angiogenic Potentialpositions (Movie S1), suggesting that angiogenic cells within SeA
sprouts can exchange places. Thus, the SeA tip cell population
scored in Figures 2C–2E likely includes both the angiogenic cells
that launched first from the aorta and kept their leading position
and those that trailed the original tip cell but later overtook it.
Prior studies suggest that migration speed is similar between
cells with differential abilities to acquire/maintain a tip cell posi-
tional status (Jakobsson et al., 2010). Of note, both WT and
obd/+ embryos form DLAVs at similar times, suggesting that
their SeA sprouts grow with matching speeds. Thus, indepen-
dently of its roles in guiding SeA sprouts (Gay et al., 2011) and
limiting EC abundance (Figures S1A and S1B), Sema-PlxnD1
signaling antagonizes angiogenic responses.
Both the angiogenic potential of obd ECs and the angiogenic
response of obd/+ ECs within WT hosts is enhanced, suggest-304 Developmental Cell 21, 301–314, August 16, 2011 ª2011 Elsevieing that Sema-PlxnD1 signaling acts prior to SeA sprouting. To
investigate this possibility and determine its potential cellular
basis, we made obd/+-to-WT and WT-to-WT chimeras and
plotted the distribution of donor ECs within the host’s trunk
vasculature shortly after SeA sprouts launch (Figure S2B).
Consistent with Sema-PlxnD1 signaling’s dispensability for
artery-vein differentiation (Torres-Va´zquez et al., 2004), ECs
from both donors contributed to the WT host’s aorta equally.
However, ECs from obd/+ donors were enriched along the
aorta’s dorsal side (Figure 2F) and obd ECs also preferentially
occupy this locale in WT hosts (Figures S1C and S2C). In
contrast, ECs with a cell autonomous impairment in down-
stream VEGF signaling that abrogates SeA angiogenesis
localize to the aorta’s ventral side within WT hosts (Covassin
et al., 2009).r Inc.
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Figure 3. Sema-PlxnD1 Signaling Ensures the Proper Endothelial Abundance of sflt1
(A) Alternative flt1 splicing yields sflt1 and mflt1 isoforms with unique eleventh exons. Exons, colored boxes. Introns, black lines.
(B) sflt1 encodes a soluble 474 aa protein. mflt1 encodes a 1,273 aa transmembrane protein. Protein domains: Immunoglobulin (Ig, red numbered boxes),
transmembrane (TM, gray box), tyrosine kinase (TK, pink box).
(C–H) WISH, embryo trunks (genotypes and ages indicated) hybridized with sflt1 (C and D, F and G) and mflt1 (E and H) riboprobes (blue).
(I) qPCR measurements. Relative mRNA abundance of sflt1, mflt1, and YFP (from Tg(flt1:YFP)hu4624/+) in 28 hpf obd/+ (WT level = 1, dashed line). Error bars
represent coefficient of variance *p < 0.05.
(J) ELISA-based quantification of FLT1 prepared from cell extracts of HUVECs treated with both VEGF and Sema3E and the control or PLXND1-targeting
shRNAs. Error bars represent SEM. ***p < 0.001.
(C–H) n = 10 embryos per riboprobe, stage and genotype. Pictures of representative examples of stainings observed (10/10 embryos in each category). Anterior,
left; dorsal, up. Scale bars represent 50 mm. See Figure S3.
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Sema-PlxnD1 Signaling Limits Angiogenic PotentialThe aorta’s dorsal side lies near the trunk’s paracrine sources
of proangiogenic VEGF (Lawson et al., 2002) and is the aortic
angiogenic region (Ahn et al., 2000; Wilkinson et al., 2009).
Importantly, obd/+ lacks aortic dorsoventral polarization
defects: bothWT and obd display similar expression of the aortic
dorsal side marker tbx20 (data not shown) and make red blood
cells, which derive from the aorta’s ventral side (data not shown)
(Wilkinson et al., 2009).
Hence, Sema-PlxnD1 signaling plays a presprouting role in
SeA angiogenesis and the cellular basis for the enhanced angio-
genic response of obd/+ arterial ECs is, at least, related to their
ability to localize early within theWT host’s aortic roof, a property
likely due to increased VEGF responsiveness. Notably, in
heterogenotypic chimeras plxnD1 genetic dosage affects aortic
cell distribution (Figure 2F) and tip cell positional status (Fig-
ure 2E) similarly but to different extents. Hence, Sema-PlxnD1
signaling likely exerts other pre-and/or postsprouting effects,
like modulating the angiogenic cell’s launching schedule and/
or positional persistence (Childs et al., 2002; Jakobsson et al.,
2010; Kearney et al., 2004).DevelopSema-PlxnD1 Signaling Regulates the Abundance
of the VEGF Antagonist Encoded by soluble flt1 (sflt1)
To determine the molecular mechanism by which Sema-PlxnD1
signaling represses angiogenic potential we usedWISH (Moens,
2008) to visualize the expression of twelve components and
targets of the VEGF and Notch signaling cascades, including
artery-vein differentiation markers (see Supplemental Informa-
tion). Only flt1 (fms-related tyrosine kinase/vegf receptor 1)
(Bussmann et al., 2007; Krueger et al., 2011) expression was
visibly affected in obd. We found that zebrafish flt1 pre-mRNA
is alternatively spliced into transcripts encoding products similar
to the soluble (sFlt1) and membrane (mFlt1) mammalian proteins
that function as high-affinity VEGF decoys or receptor/corecep-
tor tyrosine kinases, respectively (Figures 3A and 3B) (Krueger
et al., 2011; Rahimi, 2006). Using isoform-specific riboprobes
we detected sflt1 and mflt1 transcripts in the WT trunk arterial
tree at 21–28 hpf (Figures 3C–3E) (Krueger et al., 2011). In
contrast, sflt1 was barely detectable in obd despite robust
mflt1 staining (Figures 3F–3H), suggesting that Sema-PlxnD1
signaling modulates the relative abundance of flt1 isoformsmental Cell 21, 301–314, August 16, 2011 ª2011 Elsevier Inc. 305
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Sema-PlxnD1 Signaling Limits Angiogenic Potentialand/or flt1 transcription. We used qPCR to compare the mRNA
levels of WT and obd/+, which have identical EC abundances.
We measured the transcript levels of both flt1 isoforms and,
separately, quantified the YFPmRNA output of the flt1 transcrip-
tional reporter Tg(flt1:YFP)hu4624 (Hogan et al., 2009a). obd/+
shows reduced sflt1 (4-fold) and increased mflt1 (3-fold) levels,
but unaltered flt1 transcriptional levels (Figure 3I), and, confocal
imaging reveals no clear differences in Tg(flt1:YFP)hu4624 expres-
sion between WT and obd (Figure S3C). Finally, ELISA-based
measurements of FLT1 from extracts of HUVECs (human umbil-
ical vein ECs) exposed to both VEGF and the canonical PlxnD1
ligand Sema3E reveal that shRNA-mediated PLXND1 knock-
down reduces FLT1 without decreasing FLT1 transcription (Fig-
ure 3J and Figure S3A; see also Figure S3B).
We conclude that Sema-PlxnD1 signaling acts via a posttran-
scriptional mechanism to ensure sflt1’s proper abundancewithin
the trunk’s arterial tree and propose this model: sflt1 acts as
a PlxnD1 effector that antagonizes proangiogenic VEGF
signaling to limit angiogenic potential.
Partial Reduction of Both plxnD1 and sflt1 Enhances
SeA Angiogenesis
If the proposed model is true, plxnD1 and sflt1 should interact
genetically to limit SeA angiogenesis. We tested this prediction
with a morpholino (MO) (Morcos, 2007) that inhibits the alterna-
tive splicing event that yields sflt1 (Figures S4A and S4B). The
sflt1-splice MO induces aberrantly branched SeA sprouts in
WT and obd-like SeA sprout defects such as ectopic launching
and aberrant branching in obd/+ heterozygotes (Figures 4B
and 4D–4F and Figure S4C). Similarly, a pan-flt1 splice-blocking
MO (Rottbauer et al., 2005) targeting both sflt1 and mflt1 also
induces obd-like SeA sprout defects in obd/+ (Figures S4E and
S4F). Of note, a different pan-flt1 MO also induces SeA
misbranching in WT (Krueger et al., 2011). Both the expressivity
and penetrance of these abnormalities is greater in sflt1-splice
than in pan-flt1 morphants, likely due to differences in knock-
down efficiencies and the combined effects of inactivating flt1
isoforms with opposite roles (Figure 4F and Figure S4F) (Rahimi,
2006). In contrast, WT and obd/+ treated with mismatched
control sflt1 splice-blocking MO or an mflt1-specific splice-
blocking MO (Rottbauer et al., 2005) display normal SeA sprouts
(Figures 4A and 4C; Figures S4D and S4F).
These observations agree with the vascular organization roles
of plxnD1 (Gay et al., 2011) and flt1 (Krueger et al., 2011; Rahimi,
2006), the differential activities of flt1 isoforms (Chappell et al.,
2009; Kappas et al., 2008; Rahimi, 2006) and sflt1’s low level in
obd/+ (Figure 3I). In short, plxnD1 and sflt1 (but notmflt1) interact
genetically to modulate SeA sprout positioning, abundance, and
patterning.
Endothelial Overexpression of sflt1, but notmflt1,
Inhibits SeA Angiogenesis
Based on our model sflt1, like Sema-PlxnD1 signaling, should
inhibit SeA angiogenesis. We tested this idea by overexpressing
sflt1 in an endothelial-specific fashion in bothWT and obd via the
GAL4/UAS system (Figure S4G). We found that sflt1 overexpres-
sion suppresses SeA sprouting inWT and obd (Figures 4G–4H00).
To determine if mflt1 plays similar vascular roles during SeA
angiogenesis, we analyzed the effects of mflt1 overexpression.306 Developmental Cell 21, 301–314, August 16, 2011 ª2011 ElsevieThis treatment does not abrogate SeA sprouting but instead
induces ectopic SeA sprouting at low frequency, consistent
with the weak mflt1 proangiogenic activity reported (Rahimi,
2006) (Figure S4H). Hence, within the trunk vasculature sflt1
and mflt1 play distinct roles, with sflt1 acting as an inhibitor of
SeA angiogenesis.sflt1 Inhibits SeA Angiogenesis Cell Autonomously
Based on the model proposed, sflt1, like plxnD1, should act cell
autonomously within the trunk’s endothelium to suppress SeA
angiogenesis. Given the lack of flt1 mutants, we tested this
prediction by combining sflt1 overexpression with cell transplan-
tation experiments using donors and hosts carrying different
endothelial reporters to distinguish ECs according to their geno-
type. We made chimeras to determine if overexpressed sflt1
inhibits SeA sprouting non-cell-autonomously. We transplanted
obd cells into WT hosts with GAL4/UAS system-dependent
mosaic endothelial coexpression of sflt1 and fluorescent DsRed
protein. We found that WT aortic ECs overexpressing sflt1
(DsRed+) fail to form SeA sprouts. However, neighboring obd
donor and WT host aortic ECs without sflt1 overexpression
(DsRed-) form SeA sprouts (Figures 4I and 4I0). In another exper-
iment, we transplanted cells from obd donors with endothelial
sflt1 overexpression (DsRed+) into WT hosts. While the obd
aortic ECs with sflt1 overexpression (DsRed+) failed to form
SeA sprouts, neighboring WT and donor obd ECs not overex-
pressing sflt1 (DsRed-) formed SeA sprouts (Figure S4I). Thus,
sflt1 acts cell autonomously despite the potential diffusible
nature of its encoded product.The Exacerbated SeA Angiogenesis of obd Requires
VEGF Signaling
sflt1 encodes a VEGF signaling antagonist whose levels are
greatly reduced in obd (Figure 3). To test if VEGF signaling is
required for obd’s SeA angiogenesis, we chemically inhibited
VEGF receptor activation with SU5416 (Herbert et al., 2009).
SU5416, but not its vehicle (DMSO), abrogates SeA sprouting
in WT and obd (Figures 5A, 5B, 5E, and 5F; see also Figure S5B).
Similarly, MO-induced vegfa activity reduction also abrogates
obd’s SeA angiogenesis (Childs et al., 2002). These findings indi-
cate obd’s excessive SeA angiogenesis is VEGF dependent.VEGF Signaling Is Enhanced in obd
The VEGF cascade splits downstream of the VEGF receptors
into PLCG1 (phospholipase C gamma1; plcg1) and PI3Kp110a
(phosphoinositide 3-kinase p110a isoform)-dependent proan-
giogenic branches (Figure 5M) (Covassin et al., 2009; Graupera
et al., 2008). Our model predicts enhanced VEGF signaling in
obd. Hence, angiogenic deficits due to impaired VEGF signaling,
such as those of plcg1mutants, should be ameliorated in an obd
background. plcg1 lacks SeA sprouts (Figure 5C) (Covassin
et al., 2009). However, obd; plcg1 double mutants show too
many and ectopic SeA sprouts (Figure 5D and Figure S5A) that
express flt4 and a trunk arterial tree with reduced sflt1 abun-
dance (data not shown). obd; plcg1’s SeA sprouting recovery
requires VEGF signaling, sinceSU5416 suppresses it (Figure 5H).
These observations support the notion that Sema-PlxnD1
cascade inactivation enhances VEGF signaling, suggestingr Inc.
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Figure 4. plxnD1 and sflt1 Interact Genetically, sflt1 Limits SeA Angiogenesis Cell Autonomously
(A–I) Thirty-two hpf trunk vasculatures, green.
(A–E) SBs, red. White arrowheads, ectopic SeA sprouts. Blue arrowheads, ectopic SeA branching. (A, C, E) Embryos treated with 20 ng of sflt1-ctrl MO: WT (A),
obd/+ (C), obd (E). Embryos treated with 20 ng of sflt1-splice MO: WT (B), obd/+ (D).
(F) 23 hpf SeA sprout abundance in WT (left, gray bar) and obd/+ (right, black bar) sflt1-splice morphants. n = 20WT and n = 19 obd/+. Error bars represent SEM.
***p < 0.001.
(G–I0) SBs, blue. GAL4FF/UAS-mediated endothelial-specific sflt1 overexpression, red. White arrows, missing SeA sprouts.
(G0–H00) Endothelial sflt1 overexpression inhibits SeA sprouting. WT (G–G00). obd (H and H00), note lack of sflt1 overexpression (red) in remaining SeA sprout (white
arrowhead).
(I and I0) Mosaic vasculature with ECs from both obd donor and WT host. Endothelial-specific and mosaic sflt1 and DsRed coexpression restricted to the WT
endothelium (red, I and I0). obd ECs express cytosolically targeted EGFP (gray in I; green in I0). WT ECs express nuclear-targeted EGFP (white in I; green in I0). obd
andWT ECs without sflt1 overexpression (DsRed-) from SeA sprouts even next to sflt1 overexpressing WT ECs (DsRed+). WT ECs overexpressing sflt1 (DsRed+)
fail to form SeA sprouts (white arrows, I and I0).
(G–H00) n = 30 embryos with overexpression per genotype, all showing suppression of SeA sprouting. Anterior, left; dorsal, up. Scale bars represent 30 mm. See
Figure S4.
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Figure 5. Enhanced VEGF Signaling Causes obd’s Exacerbated SeA Angiogenesis
(A–L) Thirty-two hpf trunk vasculatures. WT, obd, plcg1 and obd; plcg1 treated with DMSO, SU5416 (VEGFR inhibitor), or AS605240 (PI3K inhibitor). Genotypes,
top; treatments, left. Endothelium, green. SBs, red.White arrowheads, recovered SeA sprouts in obd; plcg1. Anterior, left; dorsal, up. Scale bars represent 30 mm.
n = 18 embryos per genotype and treatment. Pictures show representative phenotypes (18/18 embryos per category).
(M) Diagram of the VEGF cascade and steps inhibited by sflt1 and drugs used in (E)–(L).
(N) HUVEC proliferation in response to combinations of VEGF, Sema3E, and shRNAs (control, PLXND1 and FLT1). ***p < 0.001. Error bars represent SEM. See
Figure S5.
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Sema-PlxnD1 Signaling Limits Angiogenic Potentialthat obd; plcg1’s angiogenic recovery is VEGF/PI3Kp110a
dependent.
We tested this possibility via chemical inhibition of PI3Kp110a
activity with AS605240 (Herbert et al., 2009). PLCG1 function
removal has a greater impact on angiogenesis than PI3Kp110a
inactivation (Covassin et al., 2009;Graupera et al., 2008). Accord-
ingly, AS605240 neither abrogates SeA angiogenesis in WT or
obd nor ameliorates plcg1’s angiogenic deficit (Figures 5I–5K).
However, AS605240 blocks SeA sprouting in obd; plcg1 (Fig-
ure 5L), indicating that proangiogenic VEGF/PI3Kp110a activity is
limiting under plcg1-deficient conditions. Hence, compared
with obd (Figure 5B), obd; plcg1 show fewer and stunted SeA
sprouts that fail to form DLAVs (Figures 1D, 5D, and 6L).
We further confirmed the link between Sema-PlxnD1 and
VEGF signaling by observing that hypomorphic mutants of kdrl,
which encodes the duplicate canonical VEGF pathway compo-308 Developmental Cell 21, 301–314, August 16, 2011 ª2011 Elsevienent VEGF receptor 2/VEGFR-2/KDR, show SeA angiogenic
deficits (Covassin et al., 2009; Habeck et al., 2002) that are
ameliorated in an obd background (Figure S5C).
To selectively determine Sema-PlxnD1 signaling’s effect on
VEGF-induced cellular responses, we used a HUVEC prolifera-
tion assay (Figure 5N). We found that VEGF-induced HUVEC
proliferation is reduced by Sema3E exposure and that the latter
effect is abrogated via PLXND1 (Bellon et al., 2010; Fukushima
et al., 2011; Sakurai et al., 2010; Uesugi et al., 2009) or FLT1
knockdown (Figure 5N and Figure S5D). Accordingly, VEGF/
Sema3E-treated HUVECsmake less FLT1 protein upon PLXND1
knockdown (Figure 3J). Of note, PLXND1 knockdown in
HUVECs does not affect FLT1 transcription (Figure S5D), paral-
leling our in vivo data indicating that Sema-PlxnD1 signaling
modulates sflt1 abundance posttranscriptionally (Figures 3C–3I
and Figure S3C).r Inc.
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Figure 6. Notch Signaling Loss Does Not Phenocopy obd
(A and B) Expression of Notch’s activity nuclear reporter Tg(Tp1bglob:hmgb1-mCherry)jh11 (red) in the endothelium (gray) of WT (A) and obd (B).
(C–F) obd; mib. (C) Endothelium, green. SBs, red. (D–F) WISH with sflt1, flt4 and mflt1 riboprobes, as indicated. Double mutant phenotypes classed as obd-like
(C and D) or mib-like (E and F) based on the mutant they resemble most. Note lack of sflt (as in Figure 3G) and ectopic aortic flt4 (yellow arrowhead; as in
Figure S6A) and venous mflt1 stainings (green arrowhead, as in Figure S6B).
(G–I) Angiogenic cell abundance within the trunk’s arterial tree of WT, obd, mib (G) and obd; mib (H) in Tg(fli1:nEGFP)y7 embryos.
(G–H) EC nuclei, green. SBs, red.
(I) Quantification; n = 10 per genotype.
(J–L) SeA sprout abundance in plcg, mib; plcg, obd; plcg (J) and obd; plcg embryos injected with 10 ng of mib MO (mib MO) (K).
(J and K) Endothelium, green. SBs, red.
(L) n = 8, 7, 11 and 9 for plcg, mib; plcg, obd; plcg and obd; plcg (mib MO), respectively.
Scale bars represent 50 mm (A, B, and D–F), 30 mm (C, G, H, J, and K).
(I and L) *p < 0.05, ***p < 0.001. Error bars represent SEM.
(A–F, G, H, J, and K) Anterior, left; dorsal, up. Trunk images and quantifications: 32 hpf (A–C, G–L), 28 hpf (D–F). See Figure S6.
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Developmental Cell
Sema-PlxnD1 Signaling Limits Angiogenic PotentialWISHs suggest that sflt1’s level in the trunk’s arterial tree is
independent of VEGF signaling: SU5416 treatment does not
reduce sflt1 abundance in WT nor increases it in obd (Fig-
ure S5B). Hence, obd’s decreased sflt1 abundance is not
secondary to enhanced VEGF signaling but rather at least one
of its causes.
Sema-PlxnD1 and Notch Signaling Play Distinct
and Additive Roles in SeA Angiogenesis
Notch signaling also negatively regulates SeA sprouting (Leslie
et al., 2007; Siekmann and Lawson, 2007). We thus compared
the arterial tree phenotypes induced by loss of Sema-PlxnD1
and Notch signaling.We found that unlike obd, SeA sprout abun-
dance and distribution are normal inmind bomb (mib) mutants, in
which a ubiquitin ligase required for Notch signaling is inactive
(Figure S6A) (Itoh et al., 2003; Lawson et al., 2002; Lawson and
Weinstein, 2002). Likewise, Notch pathway inactivation via
mutations in eithermib or delta-like ligand 4 (dll4), which encodes
a Notch ligand expressed in the trunk’s arterial tree (Leslie et al.,
2007), fails to ameliorate the angiogenic deficit of plcg1
(Figure S6C).
Studies in other systems and/or vascular beds suggest Notch
signaling promotes flt1 expression (Bussmann et al., 2011; del
Toro et al., 2010; Funahashi et al., 2010; Harrington et al.,
2008; Jakobsson et al., 2010; Suchting et al., 2007), prompting
us to ask if Notch signaling is reduced in obd or modulates the
trunk’s arterial tree expression of flt1 and its isoforms.
WISH expression analysis of Notch pathway components
(deltac, dll4 notch5, and gridlock) and targets (gridlock, ephrin-
B2a, flt4, and ephB4a) fails to uncover evidence for reduced
Notch signaling in obd (data not shown) and, endothelial
expression of the transgenic Notch signaling reporters
Tg(Tp1bglob:hmgb1-mCherry)jh11 and Tg(Tp1bglob:eGFP)um14
(Nicoli et al., 2010; Parsons et al., 2009) is similar in WT and
obd (Figures 6A and 6B and data not shown), consistent with
the notion that in obd Notch activity is preserved.
Visual comparison of the expression of the flt1 transcriptional
reporter (Hogan et al., 2009a, 2009b) in WT, obd mutants and
mib morphants (Figure S3C) reveals no significant differences.
Tg(flt1:YFP)hu4624 expression is also unaffected in dll4
morphants (Geudens et al., 2010). Moreover, WISH of mib
mutants reveals no visible reduction in sflt1 or mflt1 abundance
but rather a mild enhancement in sflt1 and mflt1 venous
expression (Figure S6B). Consistent with the role of Notch
signaling in artery/vein differentiation and angiogenesis, mib
displays ectopic aortic flt4 expression (Figure S6A) (Lawson
et al., 2001; Siekmann and Lawson, 2007).
To elucidate the relationship between Sema-PlxnD1 and
Notch signaling, we analyzed the anatomical, cellular andmolec-
ular vascular phenotypes of obd; mib and the combined impact
of inactivating both pathways on plcg1’s SeA angiogenesis
deficit. We found that within the arterial tree obd; mib show
obd-like SeA anatomical organization and sflt1 abundance
(Figures 6C and 6D) but mib-like flt4 and mflt1 expression
patterns (Figures 6E and 6F). This mix of obd- and mib-like
phenotypes reveals that Sema-PlxnD1 and Notch signaling
play distinct vascular roles.
Yet we also find additive genetic interactions between both
pathways: obd; mib have greater angiogenic cell abundance310 Developmental Cell 21, 301–314, August 16, 2011 ª2011 Elseviethan obd or mib (Figures 6G–6I) (Leslie et al., 2007; Siekmann
and Lawson, 2007). Likewise, silencing mib (Itoh et al., 2003) in
obd; plcg further increases their SeA sprout abundance (Figures
6J–6L). Hence, in this sensitized background Notch signaling
seems to play a minor role as a negative regulator of SeA sprout
abundance, consistent with the loss of SeA sprouting induced by
overexpression of constitutive-active Notch forms, the complex
interplay between VEGF and Notch signaling and the lateral
inhibition role of the latter (Jakobsson et al., 2010; Roca and
Adams, 2007; Siekmann and Lawson, 2007). While these
additive interactions suggest that Sema-PlxnD1 and Notch
signaling modulate common aspects of angiogenic develop-
ment, these pathways clearly make qualitatively and quantita-
tively different contributions via molecularly distinct mecha-
nisms. For example, while both pathways antagonize VEGF
signaling, they modulate different pathway components, namely
sflt1 and flt4. Together, these observations indicate that Notch
signaling remains active in obd and that Sema-PlxnD1 signaling
functions without Notch activity (Figure 7A), underscoring the
distinct roles of Sema-PlxnD1 and Notch signaling in SeA
angiogenesis.DISCUSSION
Our findings reveal that Sema-PlxnD1 signaling acts as a pre-
sprouting repressor of angiogenic potential in the trunk’s arterial
tree. We posit that Sema-PlxnD1 signaling fulfills this role, at
least in part, bymaintaining sflt1’s proper endothelial abundance
to antagonize proangiogenic VEGF signaling (Figure 7A). We
propose that the somitic sema3a and endothelial plxnD1 expres-
sion preceding SeA sprouting (Torres-Va´zquez et al., 2004)
(Figure 7B) reproducibly yield differences in Sema-PlxnD1
signaling level, and thus in sflt1 abundance, along the aorta (Fig-
ure 7C). Although the proposed variation in WT sflt1 aortic levels
appears beyond the resolution of WISH, we find that ECs from
obd/+ donors (which have less sflt1) are more likely to become
SeA tip cells in WT hosts. Indeed, ECs with the lowest Flt1 abun-
dance make the angiogenic sprouts of WT and Flt1lacZ/+ mouse
retinas and ES cell-derived vessels (Chappell et al., 2009).
Our WISH and qPCR data indicate that loss or reduction of
Sema-PlxnD1 signaling leads to low sflt1 abundance within
both the aorta and SeA sprouts. Accordingly, our cell transplants
show that Sema-PlxnD1 signaling acts cell autonomously to
spatially restrict the aorta’s angiogenic capacity (Figure 7D)
and limit the angiogenic responses of ECs within SeA sprouts
(Figure 7E).
While sFlt1 can act non-cell autonomously (Ambati et al.,
2006); (Chappell et al., 2009; Kearney et al., 2004), its effective
range is context dependent (Goldman et al., 1998; James
et al., 2009; Kendall and Thomas, 1993). In the trunk’s arterial
tree the antiangiogenic effects of endothelial-specific sflt1 over-
expression appear cell autonomous. sFlt1 forms VEGF-bridged
inhibitory complexes with the proangiogenic receptors Flk1/
Kdr (Bussmann et al., 2008; Kendall et al., 1996) and mFlt1
(Kendall and Thomas, 1993) and binds to the endothelial extra-
cellular matrix, which abundantly surrounds the aorta (Jin
et al., 2005; Orecchia et al., 2003). Both observations suggest
how sFlt1’s effective range might be limited within the aorta.r Inc.
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Figure 7. Model for How Sema3-PlxnD1 Signaling Restricts Angiogenic Potential along the Aorta and Limits Angiogenic Responses within
SeA Sprouts
(A) Sema3-PlxnD1 signaling inhibits VEGF’s proangiogenic effects via sFlt1, limiting angiogenic potential. The complex cross-regulation (gray lines) between the
VEGF and Notch cascades implies Sema-PlxnD1 signaling impacts Notch activity indirectly.
(B) Somitic sema3s (dark red) and endothelial plxnD1 (light red) expression precedes SeA sprouting (SB, gray) (Roos et al., 1999; Torres-Va´zquez et al., 2004; Yee
et al., 1999).
(C)WT aortic Sema-PlxnD1 signaling levels (red solid line) are highest in ECs next to the somites and lowest in ECs next to SBs, where angiogenic potential (green
solid line) is highest. obd lacks Sema-PlxnD1 activity and thus sflt1 abundance is greatly reduced (red dotted line), leading to uniformly enhanced angiogenic
potential levels (green dotted line) that yield too many and ectopic SeA sprouts.
(D and E) VEGF signaling and angiogenic responses are cell autonomously enhanced by loss (obd) or decreased (obd/+) endothelial plxnD1 activity, as
exemplified by obd to WT (D) and obd/+ to WT (E) chimeras. VEGF signaling and PlxnD1 activity levels are indicated by font size.
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proposed for mFlt1 (Lee et al., 2007b).
Our model implies that PlxnD1 signaling in response to para-
crine Sema3 cues is key for the proper spatial modulation of
angiogenic capacity within the aorta (Gay et al., 2011). Yet our
findings do not rule out the potential involvement of autocrine
Sema3cues inPlxnD1signalingprior toand/orduringSeAsprout-
ing (Banu et al., 2006; Kutschera et al., 2011; Lamont et al., 2009;
Serini et al., 2003; Toyofuku et al., 2007). Similarly, endothelial
Sema-PlxnD1 signaling could impact the proangiogenic activity
of both paracrine and autocrine VEGFs (Childs et al., 2002; Cova-
ssin et al., 2006; da Silva et al., 2010; Hogan et al., 2009b; Lee
et al., 2007a; Siekmann and Lawson, 2007; Tammela et al., 2008).
Our study reveals a key mechanistic link between
Sema-PlxnD1 and VEGF signaling (Bellon et al., 2010; Fukush-
ima et al., 2011; Sakurai et al., 2010; Uesugi et al., 2009). Consis-
tent with defects in exon selection during flt1’s alternative
splicing and/or alterations in the mRNA stability of flt1 isoforms,
impaired Sema-PlxnD1 signaling leads to contrasting posttran-
scriptional changes in sflt1 and mflt1 abundance. Sema-PlxnD1
signaling inactivates Ras-related proteins, antagonizes integrin
and PI3K signaling and modulates cytoskeletal dynamics
(Gay et al., 2011). How these PlxnD1-mediated events are con-
nected to flt1’s posttranscriptional regulation and angiogenesis
will be addressed by future studies.
Here we show that Sema-PlxnD1 and Notch signaling can
function independently of each other and play largely distinct
cellular and molecular roles. However, Sema-PlxnD1 activityDevelopantagonizes VEGF responsiveness and Notch and VEGF
signaling are linked by complex feedback loops (Jakobsson
et al., 2009; Lobov et al., 2007; Williams et al., 2006). Hence,
we anticipate functional interactions between both pathways
via the VEGF cascade. For example, it is likely that the enhanced
VEGF signaling of ECs with less Sema-PlxnD1 activity allows
them to exert a stronger Dll4/Notch-mediated lateral inhibition
upon their neighbors, enabling the former to more often become
angiogenic and/or, acquire and/or keep a tip cell positional
status (Jakobsson et al., 2010; Leslie et al., 2007; Siekmann
and Lawson, 2007). Remarkably, the combined loss of both
Sema-PlxnD1 (plxnD1) and Notch signaling (mib) signaling
does not enable every aortic EC to sprout, suggesting that other
pathways and/ormechanisms limit the trunk’s arterial tree angio-
genic capacity.
Together with prior studies (Gay et al., 2011), our findings
indicate that Sema-PlxnD1 signaling regulates distinct yet inter-
connected aspects of angiogenic development: the spatial
allocation of angiogenic capabilities and the guidance of growing
sprouts. It is likely that these roles, and their bases, are evolution-
arily conserved (see Gay et al., 2011). Changes in sflt1 abun-
dance induce congenital vascular malformations (Acevedo and
Cheresh, 2008), gestational hypertension (Rahimi, 2006) and
are associated with cancer (Aref et al., 2005). Hence, mutations
and polymorphisms that affect Sema-PlxnD1 signaling are likely
modifiers of these diseases. Conversely, alterations in sflt1
abundance and/or activity might impact Sema-PlxnD1 signaling
dependent processes like cardiovascular and nervous systemmental Cell 21, 301–314, August 16, 2011 ª2011 Elsevier Inc. 311
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Sema-PlxnD1 Signaling Limits Angiogenic Potentialdevelopment and both tumor angiogenesis and metastasis (Gay
et al., 2011; Raab and Plate, 2007; Takahashi and Shibuya,
2005). Overall, the regulation of sflt1 abundance via Sema-
PlxnD1 signaling has broad biomedical implications beyond
angiogenesis and provides a new way of understanding how
Sema and VEGF signals might be integrated in many contexts.
EXPERIMENTAL PROCEDURES
Zebrafish
Embryos and adults kept and handled using standard laboratory conditions
under New York University IACUC guidelines. Zebrafish stocks and genotyp-
ing methods/reagents described in the Supplemental Information.
Imaging
Live and fluorescently immunostained embryos imaged via confocal micros-
copy, whole mount RNA in situ hybridized embryos and drug treated animals
imaged via transmitted light microscopy. All embryos mounted sideways.
Details are in the Supplemental Information.
SeA Sprout Abundance and Position Quantification
Quantifications done using confocal images of immunofluorescently stained
23 hpf Tg(fli:EGFP)y1 embryos. SeA sprouts: individual EGFP-positive aortic
dorsal projections that reach or surpass the horizontal myoseptum (HM; see
Figure 1). SeA sprout positions: Correct (SeA base abuts directly the anterior
side of neighboring somite boundary), ectopic (all other base locations). SeA
sprouts were counted in four adjacent anterior trunk segments and averaged
to yield a SeA sprouts/somite boundary ratio. Student’s t test (homocedastic,
two-tail distribution) was used to analyze the differences between the means
of cell number data sets.
Endothelial Cell Abundance Quantification
We used 21, 23, and 32 hpf Tg(fli1:nEGFP)y7; Tg(flk1:ras-mCherry)s896 and
Tg(flk1:EGFP-NLS); Tg(flk1:ras-mCherry)s896 immunofluorescently stained
embryos to visualize EC nuclei and vascular anatomy. Confocal sections
across the width of the anterior trunk were collected and 3D-projected with
Imaris 6.2.1 software (Bitplane AG). EGFP-positive nuclei were marked
(measurement point application) and counted. Since WT SeAs launch next
to somite boundaries (SBs) but obd SeAs arise from these and other sites
we divided the trunk vasculature into segments delimited by the posterior
and anterior halves of consecutive bilateral somite pairs and counted EC nuclei
within each segment. Based on their location, EC nuclei were assigned to the
axial vessels (AxV; aorta and vein), the SeAs and/or DLAVs. AxV (rather than
aortic- and venous-specific) EC abundance was scored since the aorta and
vein are not fully distinct at 21 and 23 hpf (Herbert et al., 2009). We counted
ECs in three consecutive trunk segments (located dorsal to the yolk extension)
and averaged them to obtain ECs/bilateral somite pair ratios for each location.
Student’s t test (homocedastic, two-tail distribution) was used to analyze the
differences between the means of EC number data sets. Note: not every EC
whose nucleus is labeled by Tg(fli1:nEGFP)y7 (green) is marked by
Tg(flk1:ras-mCherry)s896 (red) due to the latter’s expression mosaicism
(Figure S1A).
Cell Transplants
Cell transplants done with 3–4 hpf donor and host blastula-stage embryos as
in (Carmany-Rampey andMoens, 2006). Thirty to 50 cells were aspirated from
the donor’s animal pole and placed into the host’s lateral margin zone. Donors
and hosts carried distinct endothelial-specific reporters to easily identify the
source of ECs within chimeras.
plxnD1’s Cell Autonomy
We used both WT and obd as Tg(fli:EGFP)y1 donors and as Tg(flk1:
ras-mcherry)s896 hosts. 1 nl of a 5% solution of lineage tracer (dextran Alexa
Fluor 647; Invitrogen) was injected into 1-cell-stage donors. Chimeras fixed
at 32 hpf.
Quantification of Mosaic SeA Sprouts with Tip Cells of Donor Origin
We used both WT and obd/+ as Tg(fli:EGFP)y1 donors and as Tg(flk1:
ras-mcherry)s896 hosts. Chimeras fixed at 28 hpf.312 Developmental Cell 21, 301–314, August 16, 2011 ª2011 ElsevieQuantification of the Distribution of ECs of Donor Origin within
the Trunk Vasculature of Chimeras
We used both WT and obd/+ as Tg(flk1:EGFP-NLS) donors. Tg(flk1:
ras-mcherry)s896 used as hosts. Chimeras fixed at 21–23 hpf. Embryos with
ECs of donor origin within the trunk’s vascular tree were selected. Confocal
images of their whole trunk vasculature were taken and analyzed as described
in Figure S2B.
sflt1’s Cell Autonomy
We used Tg(fli:EGFP)y1 donors and Tg(flk1:EGFP-NLS) hosts. Endothelial-
specific, sflt1 mosaic overexpression in donors or hosts done using the
Tg(fliep:gal4ff)ubs4 GAL4 driver line and the bidirectional UAS vector pTol
[DsRed::UAS::sFlt1].
Whole-Mount RNA In Situ Hybridization (WISH)
WISH performed as in (Moens, 2008). The list of analyzed genes and riboprobe
synthesis protocols are in the Supplemental Experimental Procedures.
Morpholino Oligo (MO) Injection
MOs (Gene Tools, LLC) were injected into 1-cell-stage Tg(fli1:EGFP)y1
embryos as in (Morcos, 2007). MO sequences and validation methods are in
the Supplemental Experimental Procedures.
Drug Treatments
Embryos were dechorionated before treatment. Treatments began at 16
(Figures 5A–5L) or 20 hpf (Figure S5B; to prevent the dramatic aortic size
reduction induced by earlier treatments). Control embryos were treated with
0.025% dimethyl sulfoxide (DMSO; Sigma) in water. Inhibitor-treated embryos
were incubated in 0.25 mM AS605240 or 0.5 mM SU5416 (Sigma) aqueous
solutions of 0.025% DMSO.
Quantitative Real-Time Polymerase Chain Reaction (qPCR)
Total mRNA (zebrafish embryos) and RNA (HUVECs) extraction and cDNA
synthesis done as per Supplemental Experimental Procedures. qPCR DNA
products amplified with Power SYBR Green 2X Master Mix (Applied Biosys-
tems) as per manufacturer’s instructions. Whole embryo qPCR products
were quantified with a 7900HT Real-Time PCR System (Applied Biosystems).
Relative sflt1, mflt1, and YFP mRNA levels normalized to bactin2 transcript
abundance. For shRNA control experiments, products were quantified with
a PRISM 7900 (Applied Biosystems). Relative PLXND1 and FLT1 levels
normalized to glyceraldehyde-3-phosphate (GAPDH) abundance. Primer
sequences are in the Supplemental Experimental Procedures.
ACCESSION NUMBERS
The sequence of the sflt1 mRNA can be accessed at GenBank (accession
number: HQ322130, released upon publication).
SUPPLEMENTAL INFORMATION
Supplemental Information includes six figures, Supplemental Experimental
Procedures, and one movie and can be found with this article online at
doi:10.1016/j.devcel.2011.06.033.
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